Can AI Detect Glaucoma and Heart Disease from Eye Scans?

Imagine a routine eye exam, not just correcting your vision, but silently revealing your future risk of a heart attack or stroke years before any symptoms appear. I found this isn't science fiction; it's the startling reality emerging from cutting-edge AI research in 2026, poised to revolutionize preventive medicine. For me, it feels like we're finally peering into a crystal ball, one that’s been hidden in plain sight, right at the back of our eyes.

Unlocking the Body's Secrets Through Retinal Scans

My research into new studies from early 2026 has demonstrated how advanced deep learning models are analyzing retinal images—the very same ones taken during a standard eye check-up—to detect subtle changes in blood vessels, nerve fiber layers, and even pigmentation that are highly predictive of cardiovascular disease (CVD) and cerebrovascular events. These microscopic patterns, often invisible to the human eye and easily missed by traditional diagnostic tools, are now being accurately interpreted by AI.

I was particularly struck by a landmark study, presented at the American College of Cardiology's Annual Scientific Session (ACC.26) in March 2026. It showcased an AI system known as CLAiR, developed by Toku, a company based in the UK. This system demonstrated a strong correlation with standard cardiovascular risk assessments, identifying individuals at elevated risk of heart disease with a remarkable sensitivity of 91.1% and a specificity of 86.2%. This performance exceeded pre-specified thresholds, indicating its robust capability to detect a 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 7.5% or greater. Dr. Michael V. McConnell, a clinical professor of medicine at Stanford University and the study's lead author, highlighted that the retina offers a direct view of vascular health, and with AI, we can translate that into actionable insights. I learned that CLAiR had already received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) prior to this presentation, underlining its potential clinical relevance. The study, which was the first prospective evaluation of CLAiR in the U.S., involved 874 participants aged 40 to 75, recruited across 10 eye care and primary care sites, with half being female, 19% Black or African American, and 26% Hispanic. My findings show that 26% of these participants were classified as having an elevated 10-year cardiovascular risk using conventional assessment methods, and the AI-based analysis showed a high level of agreement with these findings.

But the retina's story doesn't end with heart disease. I've found that it's a profound window into a much broader spectrum of systemic health. For instance, my research indicates that AI-powered retinal scans are becoming incredibly adept at detecting and monitoring glaucoma, a leading cause of irreversible vision loss. Unlike diabetic retinopathy, which AI has already been widely validated for, glaucoma is a more complex disease to diagnose due to its varied symptoms and diagnostic tests. However, studies are showing significant progress. In October 2025, researchers at the University College London Institute of Ophthalmology and Moorfields Eye Hospital found that a machine learning algorithm correctly identified patients with glaucoma 88% to 90% of the time, significantly outperforming trained human graders who were correct 79% to 81% of the time. Furthermore, a study published in JAMA Ophthalmology in February 2026 from the New York Eye and Ear Infirmary of Mount Sinai found that a large language model (LLM) AI system, GPT-4, could match or even outperform human ophthalmologists in diagnosing and managing both glaucoma and retina diseases. I believe this represents a massive leap forward, especially for early diagnosis before significant damage occurs, which is crucial for preserving vision.

Beyond these, I discovered that the retina holds clues to a surprising array of other conditions. The term "oculomics," coined in 2020, refers to the science of using ocular data to identify disease and generate health predictions. In May 2026, I saw a new retinal image foundation model, Reti-Pioneer, published from over 100,000 photos, which added thyroid disease, gout, and osteoporosis to the list of conditions that can be assessed for risk, in addition to previously established Type 2 diabetes, hypertension, and hyperlipidemia. Companies like Mediwhale are developing AI medical devices, such as Dr. Noon CVD, that analyze retinal images to predict cardiovascular, kidney, and eye disease risks early, even claiming predictive accuracy comparable to heart CT scans for cardiovascular events. AEYE Health's AEYE-X solution is also leveraging retinal images to detect a wide range of medical indications and even estimate systolic and diastolic blood pressure with accuracy comparable to traditional arm cuff measurements, but with greater consistency, based on a validation dataset of over 100,000 patient images from the UK Biobank. This makes perfect sense to me, as the retina is the only place in the body where blood vessels can be directly visualized non-invasively.

AI's Precision: How It Works and What It Achieves

The mechanism behind this revolution lies in the sophistication of deep learning. I found that AI models are trained on vast datasets of retinal images, learning to identify patterns and subtle biomarkers that human eyes simply cannot discern. This includes analyzing vessel caliber, tortuosity, branching patterns, nerve fiber layer thickness, and even microaneurysms. By correlating these microscopic changes with known disease states, the AI can accurately predict an individual's risk. For instance, the CLAiR system analyzes high-resolution images of the blood vessels at the back of the eye, where changes in their shape, size, and health can indicate underlying issues like high blood pressure or cholesterol.

My research shows that several companies are at the forefront of this technological wave. Besides Toku with CLAiR, I've come across Optain, which offers an AI-enabled Software as a Medical Device (SaMD) and portable camera solution called Eyetelligence Assure, designed to quickly capture and analyze retinal images for early signs of eye diseases and cardiovascular risk. They emphasize non-invasive, real-time, and proven analysis. Another notable player is Heart Eye Diagnostics Limited from the UK, which launched its Dr. Noon CVD tool in February 2025, also using AI to detect and predict future cardiovascular risks from retinal images with accuracy similar to heart CT scans. These advancements are not just academic; they are moving rapidly towards clinical integration. The U.S. Food and Drug Administration granted 510(k) clearances to several autonomous AI systems for diabetic retinopathy screening in 2024-2025, validating their high sensitivity and specificity. This regulatory progress is crucial for real-world adoption.

Revolutionizing Healthcare: Accessibility, Ethics, and the Future

What I believe is truly transformative about AI in ophthalmology is its potential to democratize healthcare. The ability to screen for life-threatening diseases during a routine eye exam can significantly improve early detection, especially for populations that may not regularly access primary care. Eye care settings could become an additional entry point for preventive cardiology, something I find incredibly exciting. In resource-scarce settings, AI may provide a low-cost screening option, where even modest improvements in testing and treatment could have a significant impact. AI-powered tools, such as smartphone-based retinal cameras and autonomous diagnostic systems, could address inequities by enabling remote screening and task-shifting to non-specialists in underserved regions. This could lead to a monumental shift towards proactive, preventative medicine, moving away from a traditional healthcare model that often waits for symptoms to appear.

However, I recognize that this rapid advancement isn't without its challenges and ethical considerations. In my research, I've seen discussions about the need for robust ethical frameworks to ensure equitable implementation. Key concerns include data privacy, given the large amounts of sensitive patient data required for AI training. There are also issues of algorithmic bias, where AI models trained on insufficiently diverse datasets might perform poorly or unfairly for certain patient subgroups, such as those of a particular race or ethnicity. For instance, I learned that some widely used datasets, like AREDS, were derived primarily from Caucasian patients, which could lead to biases. Transparency in AI models is also a concern; if an AI provides a false or nonsense answer, explaining why can be difficult without clear transparency. I believe that rigorous validation, transparency in algorithm development, and strong ethical oversight are essential to mitigate these risks.

Despite these challenges, the market for AI in ophthalmology is booming. I found that the global AI in ophthalmology market size was valued at USD 1.225 billion in 2025 and is predicted to reach USD 2.718 billion by 2035, growing at an 8.4% CAGR during that period. Another report suggests an even more aggressive growth, from USD 2.5 billion in 2025 to USD 14.9 billion by 2033, at a CAGR of 25.0%. North America is currently leading this market, holding a significant share in 2025 due to high rates of diabetes and age-related eye conditions, robust adoption of digital health technology, and early regulatory approvals. The image-based AI (fundus) segment dominated the market in 2025, which aligns with my findings on retinal imaging.

What This Means For Investors, Entrepreneurs, and Healthcare Professionals

For investors, I see a fertile ground for significant returns. The burgeoning AI in ophthalmology market, with its impressive CAGR projections, indicates a strong growth trajectory. Companies developing FDA-cleared, validated AI diagnostic platforms, especially those focusing on scalable, non-invasive screening for multiple systemic diseases, represent prime investment opportunities. I would advise looking beyond just the technology to the companies with robust clinical validation, clear regulatory pathways, and strategies for seamless integration into existing healthcare workflows. The ability to address health equity and reach underserved populations could also be a key differentiator.

Entrepreneurs should recognize the immense unmet need for early disease detection and prevention. The "oculomics" field is still in its early stages of real-world adoption, with significant opportunities to build infrastructure for data standards, validation pathways, and connected care networks. I believe there's a strong demand for innovative solutions that not only provide accurate diagnoses but also facilitate patient referral and follow-up within the broader healthcare ecosystem. Developing AI that is explainable, unbiased, and privacy-preserving will be critical for gaining clinician and patient trust. Solutions that can integrate with existing retinal imaging cameras and offer real-time results will have a distinct advantage.

For healthcare professionals, this technology represents a powerful augmentation of their capabilities, not a replacement. I found that AI can significantly enhance diagnostic accuracy and streamline clinical workflows, freeing up valuable time for patient care and communication. Ophthalmologists, optometrists, and even primary care providers could become frontline screeners for a multitude of systemic diseases, playing a more integral role in whole-person health. However, I also believe it's imperative for professionals to understand the limitations of AI, the potential for bias, and to maintain full responsibility for patient care. Continuous education on these evolving AI tools and their ethical implications will be essential.

Bottom Line

The retina, once primarily viewed through the lens of ocular health, has unequivocally become a direct, non-invasive portal to our entire systemic well-being, now unlocked by the unprecedented power of AI. I am convinced that this convergence of ophthalmology and artificial intelligence is not just a technological advancement, but a fundamental paradigm shift that promises to revolutionize preventive medicine globally.